The main purpose of this observational study with Irinotecan onkovis is to determine the number of treatment cycles and the quantity of Irinotecan onkovis needed for this purpose under the special circumstances of ambulant chemotherapy. Onkovis aims to contribute to an economical utilization of the chemotherapeutics. This includes provision of appropriate packaging sizes to decrease the excess quantity to be discarded, and thus also follows this objective. Secondary objective is the assessment of the side effects of Irinotecan onkovis. To this end, data regarding co-medication and adverse events are also collected.
Study Type
OBSERVATIONAL
Enrollment
324
Practice
Elstra, Germany
Practice
Leipzig, Germany
Practice
Naunhof, Germany
Practice
Neustadt/Sachsen, Germany
Practice
Werdau, Germany
The Quantity of Irinotecan onkovis needed per treatment cycle
Determine the quantity of Irinotecan onkovis needed pro treatment cycle
Time frame: up to 24 weeks
Adverse events during and after treatment
The number and kind of adverse events during and after the intra-venous application of Irinotecan will be assessed and documented.
Time frame: up to 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.